Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
НоваРинг – контрацепция, анатомия, сексология
НоваРинг – контрацепция, анатомия, сексология
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Ballgh AO, Mishell DR, Lacarra M et al. A contraceptive vaginal ring releasing norethindrone acetate and etinyl estradiol. Contraception 1994; 50: 517–33.
2. Dieben TOM, van Beek A, Coelingh Bennink HJ et al. Efficacy, cycle control and user acceptability of a novel combined contraceptive vaginal ring. Manuscript in preparation. 2002.
3. Duijkers I, Kilick S, Bigrigg A et al. A comparative study on the effects of a contraceptive on carbohydrate metabolism and adrenal and thyroid function. Contraception 2004; p. 131–40.
4. Mishell DR, Talas M, Parlow AF, Moyer DL. Contraception by means of silastic vaginal ring impregnated with medroxyprogesteron acetate. Am J Obstet. Gynecol 1970; 107: 100–7.
5. Mishell DR, Moore DE, Roy S, Brenner PF, Page MA. Clinical perfomance and endocrine profiles with contraceptive vaginal ring containing a combination of estradiol and d-norgestrel. Am J Obstet Gynecol 1978; 130: 55–62.
6. Novak A, de la Lodge C, Abetz L.valuation of NuvaRing acceptability in 14 countries. Presented at the 17th World Congress of Feritity and Sterility, Melbourne, 2001.
7. Roumen FJME, Dieben TOM, Assendorp R. The clinical acceptability of a non-medicated vaginal ring. Contraception 1990; 42: 201–7.
8. Roumen FJME, Apter D, Mulders TMT et al. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinylestradiol. Hum Reprod 2001; 16: 469–75.
9. Roumen FJME, Boon ME, van Velzen D et al. The cervico-vaginal epithelium during 20 cycles use of a combined contraceptive vaginal ring. Hum . Reprod 1996; 11: 2443–8.
10. Timmer CJ, Mulders TMT. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000; 3: 233–42.
2. Dieben TOM, van Beek A, Coelingh Bennink HJ et al. Efficacy, cycle control and user acceptability of a novel combined contraceptive vaginal ring. Manuscript in preparation. 2002.
3. Duijkers I, Kilick S, Bigrigg A et al. A comparative study on the effects of a contraceptive on carbohydrate metabolism and adrenal and thyroid function. Contraception 2004; p. 131–40.
4. Mishell DR, Talas M, Parlow AF, Moyer DL. Contraception by means of silastic vaginal ring impregnated with medroxyprogesteron acetate. Am J Obstet. Gynecol 1970; 107: 100–7.
5. Mishell DR, Moore DE, Roy S, Brenner PF, Page MA. Clinical perfomance and endocrine profiles with contraceptive vaginal ring containing a combination of estradiol and d-norgestrel. Am J Obstet Gynecol 1978; 130: 55–62.
6. Novak A, de la Lodge C, Abetz L.valuation of NuvaRing acceptability in 14 countries. Presented at the 17th World Congress of Feritity and Sterility, Melbourne, 2001.
7. Roumen FJME, Dieben TOM, Assendorp R. The clinical acceptability of a non-medicated vaginal ring. Contraception 1990; 42: 201–7.
8. Roumen FJME, Apter D, Mulders TMT et al. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinylestradiol. Hum Reprod 2001; 16: 469–75.
9. Roumen FJME, Boon ME, van Velzen D et al. The cervico-vaginal epithelium during 20 cycles use of a combined contraceptive vaginal ring. Hum . Reprod 1996; 11: 2443–8.
10. Timmer CJ, Mulders TMT. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000; 3: 233–42.
Авторы
В.Н.Прилепская
ГУ Научный центр акушерства, гинекологии и перинатологии
(дир. – акад. РАМН В.И.Кулаков) РАМН, Москва
ГУ Научный центр акушерства, гинекологии и перинатологии
(дир. – акад. РАМН В.И.Кулаков) РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.